Résumé :
|
[BDSP. Notice produite par INIST-CNRS R0xr8lDJ. Diffusion soumise à autorisation]. Since 1997, the Advisory Committee on Immunization Practices has recommended the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for nonelderly adults with certain medical conditions. In 2008, the Committee added asthma and cigarette smoking to the list of indications for PPSV23 vaccination. Using data from the 2009 National Health Interview Survey, the authors assessed PPSV23 uptake in people with established and new indications. To identify factors independently associated with receiving PPSV23, they used multivariable logistic regression and predictive marginal analyses. In 2009, a total of 35.2 million adults 18-64 years of age (18.6 %) had established PPSV23 indications ; adding asthma and smoking to the list of indications increased the high-risk population to 71.6 million people (37.9 %). Overall, 26.1 % of people with established indications for PPSV23 and 17.4 % of people with any indication (those previously established, as well as asthma and smoking) had received the vaccine ; overall coverage among persons 50-64 years of age was significantly higher than that among persons 18-49 years of age (34.6 % vs. 16.7 % ; P
|